Hello Fellow Patriots,

Two headlines hit the market with very different vibes, but they rhyme in one important way: growth stories can change fast.

Hims & Hers Health (HIMS) got hammered in premarket trading after it said it would stop selling a compounded semaglutide pill that looked a lot like a cheaper Wegovy alternative. The drop was swift, because investors hate one thing more than bad numbers: uncertainty about what a company is allowed to sell.

At the same time, OpenAI’s ChatGPT keeps posting mind-bending scale. Recent coverage has pointed to roughly 800 million weekly active users, with reports suggesting growth has returned to more than 10% month over month and that coding usage has spiked. That kind of adoption can turn an app into a habit, and a habit into a platform.

This breakdown explains what happened, why the market reacted the way it did, and what to watch next, without getting lost in hype or panic.

Why HIMS dropped so fast in premarket, and what the halted “copycat” weight loss pill signals

HIMS didn’t fall because people suddenly stopped wanting weight-loss meds. It fell because the company stepped into one of the most sensitive zones in US healthcare: compounded versions of blockbuster drugs, sold at scale, with regulators and patent owners watching closely.

Reports pegged the premarket slide at roughly 15%, and the selling pressure didn’t stop there. In the regular session, the stock traded sharply lower at points, dipping below $20 and later closing around $19.33 (down about 16% on the day). In plain English, the market was repricing the odds that Hims’ GLP-1 momentum could keep rolling without hitting a wall.

The trigger was a quick sequence of events. Hims moved to offer a compounded semaglutide pill at a very low introductory price compared with branded options. Novo Nordisk, which owns Wegovy and defends its intellectual property aggressively, signaled it would sue for patent infringement. Around the same time, regulators publicly signaled tougher enforcement toward mass-market “copycat” compounding. Within days, Hims said it would discontinue the product after discussions with stakeholders.

That back-and-forth matters because investors don’t just price today’s revenue. They price the reliability of next quarter’s revenue. When a product sits in a gray area, the discount rate goes up. Fast.

Compounding, FDA scrutiny, and the patent fight, explained like you are talking to a friend

Compounding is basically a pharmacy making a custom version of a medication. Think of it like a tailor. If a patient needs a different dose, a different form (pill instead of injection), or there’s a shortage of the commercial product, compounding can fill a real gap.

That’s the “why it exists” part.

The risk shows up when compounding stops looking like custom care and starts looking like a large-scale substitute for a brand-name drug. Regulators pay attention because they’re responsible for safety and supply chain controls. Brand owners pay attention because a copycat product, even if framed as compounded care, can undercut their pricing and their patents.

In this case, Novo Nordisk has taken legal action, arguing that Hims violated rights tied to a key US patent connected to semaglutide. Hims, for its part, has said the lawsuit is an attack on access for people who rely on compounded medications. Both positions can be “on brand” for the parties involved, but the market mostly hears one thing: headline risk that can turn into sales limits.

It’s not a legal conclusion to say this is messy. It’s just the reality of mixing high demand, high prices, and products that sit near regulatory tripwires.

Is this a one-time product hiccup, or a bigger hit to HIMS’s GLP-1 growth story?

Investors are now forced to ask a blunt question: was the compounded pill a side quest, or was it a pillar?

The bear case is straightforward. If Hims has to pull back from mass-market compounded GLP-1 offerings, expectations for weight-loss revenue may reset. Legal bills could rise. Partnerships and suppliers may get cautious. Even if the company can offer other GLP-1-related services, the easiest growth path, cheap and widely marketed alternatives, could narrow.

The bull case is also real. Hims is not a single-product company. It has a broad telehealth engine that sells and supports treatments across categories such as hair loss and sexual health. The business has shown strong operating growth recently, including reporting around 2.5 million subscribers and sharp year-over-year revenue gains in recent quarters (one recent quarter was cited at roughly 49% growth, with revenue around $599 million). Even critics often admit the company is good at customer acquisition and retention marketing.

So why the violent move in the stock? Because when a company’s narrative tilts toward “GLP-1 winner,” the market rewards it. When that same narrative starts sounding like “GLP-1 depends on regulators and courtrooms,” volatility spikes. And HIMS has a history of wide price swings, which makes forced selling and quick sentiment shifts more likely.

ChatGPT at about 800M weekly active users, what that number really means for the AI race

Weekly active users (WAU) sounds like a boring metric until you compare it to everything else people cite. Downloads can be inflated by curiosity. Monthly users can hide churn. Weekly use is closer to habit.

Recent reporting has put ChatGPT at roughly 800 million weekly active users as of early 2026. For context, that’s an audience bigger than many continents. It also signals something simple: AI chat is no longer a niche tool for tech workers. It’s showing up in study routines, office workflows, customer support scripts, and coding.

There are other signs of scale too. Public estimates have pointed to users sending billions of prompts per day, and web traffic at a level that puts ChatGPT among the most visited properties online. None of that guarantees profit, but it does suggest a durable behavior change: people now “ask the model” the way they used to “search the web.”

Competition is tightening, though. Rivals have grown quickly, and some market share measures, especially on mobile, show the field getting more crowded. That’s normal when a new category goes mainstream. When the prize is this big, nobody sits out.

The investor lesson is that ChatGPT’s number is less about bragging rights and more about positioning. The company that becomes the default assistant gets repeated chances to sell upgrades, enterprise plans, developer tools, and add-ons. Habit creates distribution, distribution lowers friction, and friction is where most new products die.

How ChatGPT got this big so quickly, and what is driving the next wave of use

ChatGPT’s growth curve has been unusually steep. Public reporting has suggested it was around 400 million weekly users in early 2025, then surged to 800 million within months. After that, coverage has suggested the user base has hovered in that range while continuing to expand again into early 2026.

What’s pushing the next wave isn’t just casual Q&A. It’s work.

Reports around OpenAI’s internal updates have suggested ChatGPT has returned to 10%+ month-over-month growth, even with competitors spending heavily. There have also been reports of a sharp spike in coding-related usage, with Codex usage rising quickly in a short window, plus signals that OpenAI planned a fresh chat model update.

The “coding” part matters because it’s closer to ROI than novelty. Developers can measure time saved. Teams can track cycle time. Leaders can justify a paid tool when it helps ship product faster.

Recent product coverage also pointed to OpenAI releasing a newer Codex-focused model in early February 2026, aimed at faster coding performance and better multi-language output. Whether you love or hate AI coding assistants, the adoption is hard to ignore. It’s spreading through IDE extensions, command-line tools, and web apps where developers already live.

Big user numbers do not automatically mean big profits, here is what to watch

A huge user base can still be a money pit if costs rise faster than revenue. AI models are expensive to run. Every prompt has a compute bill behind it, and the most capable models tend to cost more.

Monetization can come from a few places:

• Paid plans for individuals who want better models, speed, and features
• Enterprise deals that bundle security, admin controls, and data handling terms
• API usage that plugs models into other apps
• Developer tools like coding assistants that can justify recurring spend

At the same time, adoption inside big companies can be slower than the headlines suggest. Many teams won’t rush into broad rollouts if they worry about data exposure, compliance, or employees pasting sensitive info into the wrong box.

If you want proof points that matter more than hype, keep a short watchlist:

• Enterprise adoption: named wins, renewals, and expansion inside large orgs
• Retention: do people keep using it weekly after the first month?
• Reliability: uptime, speed, and error rates as usage grows
• Product cadence: meaningful model releases and tools that reduce cost per task

Those indicators tell you whether 800 million weekly users is a peak, a plateau, or a base camp.

What these stories teach investors about regulation risk vs platform momentum

Put HIMS and ChatGPT side by side and you get a clean contrast.

Hims shows how a fast-growing business can get punished when a key product line depends on rules, enforcement priorities, and patent disputes. Even if the company has real customer demand, the market will haircut the story when it can’t estimate what’s allowed next month.

ChatGPT shows the other side. When a tool becomes a default behavior, it gains momentum that’s hard to copy. Competitors can match features, but habits are sticky. That doesn’t make it an automatic winner, but it does change the odds.

For everyday investors, the key is to separate two kinds of risk:

• Boundary risk (regulators, courts, patents, and product permission)
• Execution risk (costs, competition, trust, and turning usage into cash)

Both can sink a stock, but they move on different timelines. Boundary risk can hit overnight. Execution risk often shows up quarter by quarter.

A simple framework for reading the next headline without overreacting

When a scary headline lands, it helps to run a quick mental checklist.

First, name the risk type. HIMS is a mix of regulatory and legal risk. ChatGPT’s biggest risks are competition, cost, and trust.

Second, decide if the hit looks temporary or structural. A temporary hit is a shipping delay or a one-off outage. A structural hit is “you can’t sell that product the way you planned.” Hims pulling a compounded semaglutide pill feels closer to structural until proven otherwise, because it changes the menu.

Third, look for leading indicators, not vibes. For Hims, that’s guidance changes, product lineup updates, and how management talks about GLP-1 plans. For OpenAI’s ecosystem, it’s whether weekly usage keeps climbing, whether businesses sign broader contracts, and whether developer adoption stays hot.

Fourth, size your risk to the uncertainty. If the story depends on court outcomes or enforcement actions, treat it with extra caution. If the story depends on execution, you usually get more time to watch the trend.

What to watch next week and next quarter for HIMS and for OpenAI’s ecosystem

For Hims, the near-term calendar matters. The company has an earnings update scheduled soon (late February 2026), and investors will listen for plain answers on GLP-1 strategy after discontinuing the compounded pill. Beyond earnings, keep an eye on:

• Updates in the Novo Nordisk lawsuit and any early court signals
• Any broader FDA communication or enforcement actions tied to mass-market compounding
• Product changes that show whether GLP-1 becomes smaller, different, or more service-based
• Language around supply, pharmacy partners, and what “compliance-first” looks like in practice

For OpenAI and ChatGPT, the watch items are less about one lawsuit and more about momentum and monetization:

• Confirmation of the next major model release timing and what improves for users
• Whether reported 10%+ monthly growth holds up for more than a burst
• Enterprise announcements that show large organizations committing long-term
• Whether Codex and coding tools keep growing, since they can drive paid adoption

None of this requires predicting the future. It’s about tracking what changes the odds.

Conclusion

HIMS and ChatGPT tell the same story from opposite angles. Hims stepped into a high-demand market through a route that drew patent pressure and tighter regulatory attention, and the stock got hit hard once the company pulled the product. ChatGPT’s roughly 800 million weekly active users shows AI is now a mainstream habit, but turning that habit into durable profit still depends on trust, cost control, and paid adoption.

If you’re following either story, focus on primary updates and clear indicators, not the loudest take on your timeline. The best investing decisions usually come from staying calm when the crowd isn’t. Keep your eye on what changes the long-term narrative, and let the rest be noise.

Trade Like A Pro

Introducing our newest addition to Patriot Market Research!  PMR Stock Tracker App. With this tool our fellow Patriots will receive the most detailed and updated data, analytics, charts, trading signals, market insight, analysis, sentiment and quantitative ratings In Real Time. Join Patriot Market Research club membership at pmrclub.com. Once you have joined, you will get a complete list of A+ Rated Assets: stocks, commodities, dividends, futures and cryptocurrency, updated in real time to your personal dashboard. As a special bonus, we will keep you updated with Patriot Power Plays, Patriot News, and Patriot Roundtable to get complete asset trading and training articles with insight and expert analytics through quantitative real time analysis. Don't just follow social media headlines. Know the data before the headlines. Stay one step ahead of the market and two steps ahead of the average investor.